Dr. Laura Sepp-Lorenzino joins Lexeo Therapeutics (LXEO) board and science committee. Filing Impact (Moderate) Filing Sentiment Rhea-AI Filing summary. Lexeo Therapeutics, Inc. appointed Dr. Laura Sepp-Lorenzino to its board of directors effective April 28, 2026. She will serve until the company's 2028 annual meeting of stockholders and has also been named to the company's Science and Technology Committee. Dr. Sepp-Lorenzino brings extensive experience from leadership and scientific roles at multiple biotechnology and pharmaceutical companies and currently leads a consulting firm focused on genomic medicine. Under Lexeo's non-employee director compensation policy, she will receive $40,000 in annual cash compensation and an initial option to purchase 50,000 shares, with future annual option grants of 25,000 shares beginning with the 2027 annual meeting. 8-K event classification. Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Key figures. Appointment date: April 28, 2026 Board term end: 2028 annual meeting Annual cash compensation: $40,000 +3 more Key terms. Non-Employee Director Compensation Policy, indemnification agreement, Item 404(a) of Regulation S-K, Science and Technology Committee, +1 more 04/30/2026 - 04:00 AM Faq. What did Lexeo Therapeutics (LXEO) announce in this 8-K filing? Lexeo Therapeutics announced the appointment of Dr. Laura Sepp-Lorenzino to its board of directors, effective April 28, 2026. She will serve until the 2028 annual meeting and join the Science and Technology Committee, bringing extensive genomic medicine and biopharmaceutical leadership experience. Who is Dr. Laura Sepp-Lorenzino, the new Lexeo Therapeutics (LXEO) director? Dr. Laura Sepp-Lorenzino is a biochemist and industry leader who has held senior roles at Intellia Therapeutics, Vertex Pharmaceuticals, Alnylam Pharmaceuticals, and Merck. She now leads GNMmeds LLC and serves on several biotech boards, adding deep genomic medicine and RNA therapeutics expertise to Lexeo. What compensation will Dr. Sepp-Lorenzino receive as a Lexeo Therapeutics (LXEO) director? Under Lexeo's non-employee director compensation policy, Dr. Sepp-Lorenzino will receive $40,000 in annual cash compensation for board service. She also received an initial stock option for 50,000 shares and is eligible for future annual option grants of 25,000 shares, subject to policy terms. When will Dr. Sepp-Lorenzino receive annual equity grants from Lexeo Therapeutics (LXEO)? Annual option grants of 25,000 shares begin with the 2027 annual meeting of stockholders. Because her appointment date is within six months of the 2026 annual meeting, the policy makes her ineligible for an annual grant tied to the 2026 meeting, delaying recurring awards until 2027. Does Dr. Sepp-Lorenzino have any related-party transactions with Lexeo Therapeutics (LXEO)? Other than Lexeo's standard indemnification agreement, the company states Dr. Sepp-Lorenzino has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K, and no such transactions are currently proposed, limiting potential related-party concerns. Are there special arrangements behind Dr. Sepp-Lorenzino's appointment to Lexeo Therapeutics (LXEO)? Lexeo states there are no arrangements or understandings with any persons under which Dr. Sepp-Lorenzino was appointed as director, and no family relationships with existing directors or executive officers. This indicates a standard, independent board appointment process consistent with typical corporate governance practice. Filing exhibits & attachments. 1 document

Lexeo Therapeutics announces research collaboration to explore targeted cardiac delivery of AAV gene therapy. Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson's expertise in cardiovascular therapeutics and circulatory technologies, including Impella(TM) heart pumps NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) - Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a research collaboration with Johnson & Johnson, a global leader in cardiovascular health, to investigate localized cardiac delivery of gene therapy. The collaboration seeks to advance the potential efficacy and safety profile of gene therapy for genetically mediated cardiovascular diseases by concentrating AAV (adeno associated viral) delivery to the heart by investigating cutting-edge routes of administration using Impella(TM) heart pump technology. Impella heart pumps provide direct cardiac unloading to enhance myocardial perfusion, which may help delivery of gene therapy. "This collaboration represents an exciting step toward unlocking the full potential of cardiac gene therapy," said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. "By concentrating delivery to the heart with localized routes of administration leveraging Impella heart pumps, we aim to substantially reduce required AAV doses and improve gene therapy safety while maximizing transgene expression and clinical efficacy. We are thrilled to pair Lexeo's leadership in cardiac genetic medicine with Impella's world-class technology to advance a next generation of targeted genetic medicines for cardiovascular disease." About Lexeo Therapeutics Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, LX2020 for the treatment of plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need. Cautionary Note Regarding Forward-Looking Statements Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Lexeo's expectations regarding the partnership and potential of genetic medicines to treat cardiac diseases. Words such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "develop," "plan" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo's filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company's control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: risks and uncertainties related to global macroeconomic conditions and related volatility; expectations regarding the initiation, progress, and expected results of Lexeo's preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 5, and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law. Media Response: [email protected] Investor Response: Ashley Kaplowitz [email protected]

Lexeo Therapeutics to present at the 44th Annual J.P. Morgan Healthcare Conference. December 22, 2025 07:30 ET | Source: Lexeo Therapeutics NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) - Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 7:30 AM PT in San Francisco, California. The event will be webcast live under the News & Events tab in the Investors section of the Company's website. A replay of the webcast will be available on the website following the presentation. About Lexeo Therapeutics Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, LX2020 for the treatment of plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.